Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.50 |
| ▸ | PPARA | Q07869 | 10/20 | 0.50 |
| ▸ | PPARG | P37231 | 8/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.48 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3978038 | 0.89 | PPARD (0.52) | PPARDPPARAPPARGNR1H2NR1H3 | |
| SCHEMBL3977194 | 0.86 | PPARD (0.49) | PPARDPPARAPPARGNR1H2NR1H3 | |
| SCHEMBL3984175 | 0.86 | PLA2G4B (0.45) | PPARDPPARAPPARGNR1H2NR1H3 | |
| SCHEMBL3977237 | 0.83 | NR1H2 (0.48) | PPARDPPARAPPARGNR1H2NR1H3 | |
| SCHEMBL3981193 | 0.82 | TDP1 (0.56) | PPARDPPARAPPARGNR1H2NR1H3 | |
| SCHEMBL3981346 | 0.79 | NR1H2 (0.53) | PPARDPPARANR1H2NR1H3 | |
| SCHEMBL3981345 | 0.79 | NR1H2 (0.53) | PPARDPPARANR1H2NR1H3 | |
| SCHEMBL3981348 | 0.79 | NR1H2 (0.53) | PPARDPPARANR1H2NR1H3 | |
| SCHEMBL3980716 | 0.78 | NR1H2 (0.56) | PPARDPPARAPPARGNR1H2NR1H3 | |
| SCHEMBL3976116 | 0.75 | NR1H2 (0.46) | PPARDPPARAPPARGNR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473705-B2 | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-01-06 | — | — | US | claimed |
| EP-1802566-B1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-26 | — | — | EP | claimed |
| EP-1802566-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | claimed |
| WO-2006037480-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | claimed |
| US-20060074115-A1 | Novel hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | claimed |
| US-7473705-B2 | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-01-06 | — | — | US | disclosed |
| EP-1802566-B1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-26 | — | — | EP | disclosed |
| EP-1802566-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006037480-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074115-A1 | Novel hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074115-A1 | Novel hexafluoroisopropanol substituted ether derivatives | NR1H3, NR1H2, NR1I2 | PPARD 10/4885PPARA 23/4885PPARG 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.